Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
The unique ORS effervescent tablet has been developed according to the latest guidelines of the WHO. It has a substantial marketshare in several countries. We are looking for partners to further expand this success. More
The development of a transdermal therapeutic system offers the advantages of constant plasma levels i.e. avoiding of plasma peaks and providing of therapeutic plasma level during the early morning hours More
Adhesive patch containing and delivering essential and balsamic oils for the symptomatic treatment of the common cold and nasal congestion More
Proprietary supercritical fluid (SCF) technology to improve bioavailability, enhance stability and optimise drug delivery for small and large molecules in a range of dosage forms. More
Multilayered controlled release oral solid pharmaceutical composition in tablet form suitable for oral administration comprising at least two layers containing active material in association with excipients and additives. More
Supercritical fluid crystal and particle engineering to form particles with strong aerodynamic performance and exceptional size uniformity for optimised pulmonary/nasal delivery More
Enhancing the dissolution performance of small and large molecules in a range of dosage forms More
Improving the reconstitution and increasing the stability of biomolecules using supercritical fluid (SCF) processing More
Spraying a tannin-rich hypertonic solution on the throat surface generates hypotonic fluid exudation, detaching all contaminants, hydrating the throat and alleviating the pain. Virus neutralization inhibits further infection. For adults and children. More
Nesosprayis a non-irritant, hypertonic spray for the treatment of acute and chronic Rhinosinusitis. More
Related Reports
Market Research Reports provided by reports.iptechex.com
Nov 2010 - 428 pages - $2,695
Nov 2010 - 178 pages - $1,495
Jan 2011 - 124 pages - $1,740
Nov 2010 - 160 pages - $1,495
Jun 2009 - 118 pages - $1,040
Nov 2009 - 830 pages - $1,040
Jun 2009 - 110 pages - $1,040
Feb 2010 - 155 pages - $3,835
Jul 2011 - 82 pages - $500
Oct 2011 - 60 pages - $500
Your selection
Browse By
- Industry sector
- Intravesical
- Nasal
- Nasal topical
- Ophthalmic
- Oral liquid
- Oral solid
- Otic
- Parenteral
- Pulmonary
- Rectal
- Systemic
- Topical
- Vaginal
- Therapeutic target
- Adult respiratory distress syndrome
- Allergy, respiratory
- Asthma
- Asthma, bronchospasm
- Bronchitis
- Chest disorder (other)
- Chlamydia pneumoniae
- Chronic obstructive pulmonary disease
- Cough
- Cystic fibrosis
- Dysplasia, bronchopulmonary
- Emphysema
- Granulomatous lung disease sarcoidosis
- Idiopathic respiratory distress syndrome
- Meconium aspiration syndrome
- Nasal disorder (other)
- Obstructive airway disease
- Pneumonia
- Pneumonocystis carinii lung infection
- Pseudomonas lung infection
- Respiratory disorder (other)
- Respiratory syncytial virus
- Respiratory tract infections
- Rhinitis
- Rhinovirus (common cold)
- Sinusitis
- Sleep apnea
- Throat disorder (other)
- Tuberculosis
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us